Effectiveness of direct oral anticoagulants for all-cause mortality and cardiovascular events in overweight and obese patients with atrial fibrillation: Insight from the nationwide START registry.

ABSTRACT:

Background

Overweight and obesity are highly prevalent in atrial fibrillation (AF) patients, yet the best anticoagulant strategy for this group is still unclear. We evaluated the risk of all-cause mortality and cardiovascular events (CVEs) in overweight and obese AF patients treated with direct oral anticoagulants (DOACs) or vitamin K antagonists (VKAs).

Methods

We analysed 10,259 AF patients on anticoagulants from the prospective nationwide START registry. Overweight was defined as BMI 25-29.9 kg/m² and obesity as BMI ≥30 kg/m². Mortality risk was assessed with Cox proportional hazards models, and CVEs with Fine-Grey models accounting for competing risks. Additional modelling strategies, subgroup analyses, and propensity score matching were performed t

SUBMITTER: Menichelli D 

PROVIDER: S-EPMC12820908 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature